Suppr超能文献

新出现的实体:伴有 11q 异常的高级别/大 B 细胞淋巴瘤、伴有 IRF4 重排的大 B 细胞淋巴瘤和大 B 细胞淋巴瘤中的新分子亚群。EA4HP/SH 淋巴瘤研讨会 2022 年报告。

Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.

机构信息

Institute of Pathology and Neuropathology, Eberhard-Karls-University of Tübingen and Comprehensive Cancer Center, University Hospital Tübingen, Liebermeisterstrasse 8, 72076, Tübingen, Germany.

Cluster of Excellence iFIT (EXC2180) "Image-guided and functionally Instructed Tumor therapies" Eberhard-Karls-University, Tübingen, Germany.

出版信息

Virchows Arch. 2023 Sep;483(3):281-298. doi: 10.1007/s00428-023-03590-x. Epub 2023 Aug 9.

Abstract

Emerging entities and molecular subgroups in large B-cell lymphomas (LBCLs) were discussed during the 2022 European Association for Haematopathology/Society for Hematopathology workshop in Florence, Italy. This session focused on newly recognized diseases and their diagnostic challenges. High-grade/large B-cell lymphoma with 11q aberration (HG/LBCL-11q) is defined by chromosome 11q-gains and telomeric loss. FISH analysis is recommended for the diagnosis. HG/LBCL-11q can occur in the setting of immunodeficiency, including ataxia-telangiectasia, and predominates in children. The morphological spectrum of these cases is broader than previously thought with often Burkitt-like morphology and coarse apoptotic bodies. It has a Burkitt-like immunophenotype (CD10+, BCL6+, BCL2-) but MYC expression is weak or negative, lacks MYC rearrangement, and is in contrast to Burkitt lymphoma 50% of the cases express LMO2. LBCL with IRF4 rearrangement (LBCL-IRF4) occurs mainly in the pediatric population but also in adults. LBCL-IRF4 has an excellent prognosis, with distinguishing molecular findings. IRF4 rearrangements, although characteristic of this entity, are not specific and can be found in association with other chromosomal translocations in other large B-cell lymphomas. Other molecular subgroups discussed included primary bone diffuse large B-cell lymphoma (PB-DLBCL), which has distinctive clinical presentation and molecular findings, and B-acute lymphoblastic leukemia (B-ALL) with IGH::MYC translocation recently segregated from Burkitt lymphoma with TdT expression. This latter disorder has molecular features of precursor B-cells, often tetrasomy 1q and recurrent NRAS and KRAS mutations. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.

摘要

在意大利佛罗伦萨举行的 2022 年欧洲血液病理学协会/血液病理学学会研讨会上,讨论了大 B 细胞淋巴瘤(LBCL)中的新兴实体和分子亚群。本次会议重点讨论了新发现的疾病及其诊断挑战。11q 异常的高级别/大 B 细胞淋巴瘤(HG/LBCL-11q)定义为染色体 11q 增益和端粒缺失。建议进行 FISH 分析以进行诊断。HG/LBCL-11q 可发生在免疫缺陷的情况下,包括共济失调毛细血管扩张症,并且在儿童中更为常见。这些病例的形态学谱比以前认为的更广泛,通常具有类似于伯基特淋巴瘤的形态和粗糙的凋亡小体。它具有类似于伯基特淋巴瘤的免疫表型(CD10+,BCL6+,BCL2-),但 MYC 表达较弱或阴性,缺乏 MYC 重排,与伯基特淋巴瘤相反,50%的病例表达 LMO2。IRF4 重排的 LBCL(LBCL-IRF4)主要发生在儿童人群中,但也发生在成人中。LBCL-IRF4 具有良好的预后,具有独特的分子发现。IRF4 重排虽然是该实体的特征,但并不特异,并且可以在其他大 B 细胞淋巴瘤中与其他染色体易位相关联时发现。讨论的其他分子亚群包括原发性骨弥漫性大 B 细胞淋巴瘤(PB-DLBCL),其具有独特的临床表现和分子发现,以及最近从具有 TdT 表达的伯基特淋巴瘤中分离出来的具有 IGH::MYC 易位的 B 急性淋巴细胞白血病(B-ALL)。后一种疾病具有前体细胞 B 细胞的分子特征,通常为四体性 1q 和复发性 NRAS 和 KRAS 突变。在本报告中,将讨论研讨会提交的病例提出的新发现、诊断建议、未解决的问题和诊断挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1046/10541818/4f2686c67706/428_2023_3590_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验